A
12.72
-0.16 (-1.24%)
| Penutupan Terdahulu | 12.88 |
| Buka | 12.92 |
| Jumlah Dagangan | 774,187 |
| Purata Dagangan (3B) | 2,123,450 |
| Modal Pasaran | 726,119,168 |
| Harga / Jualan (P/S) | 1.03 |
| Harga / Buku (P/B) | 5.21 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2025 |
| EPS Cair (TTM) | -1.88 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.75% |
| Nisbah Semasa (MRQ) | 17.39 |
| Aliran Tunai Operasi (OCF TTM) | -96.14 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -62.11 M |
| Pulangan Atas Aset (ROA TTM) | -22.56% |
| Pulangan Atas Ekuiti (ROE TTM) | -32.89% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Astria Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.8 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 0.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | 0.0 |
| Persekitaran Makro | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -0.47 |
|
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.49% |
| % Dimiliki oleh Institusi | 106.43% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |